IN8bio reports Q2 net loss of $5.1M; 4-year PFS milestone in glioblastoma trial

IN8BIO, INC.

2025-Q2 EPS reported -$3.65

Net loss $5.1M ($1.24/sh) vs $8.6M ($5.51/sh) in Q2 2024; R&D expenses down to $2.5M from $5.2M.
Cash $13.2M as of June 30, 2025 (up from $10.2M year ago); runway extended into June 2026.
INB-200 trial patient surpasses 4 years without progression; mPFS 16.1 months for multi-dose patients (standard of care 6.9 months).
Preclinical data at ASGCT 2025: INB-619 achieves complete B cell depletion in lupus samples without significant inflammatory cytokines.
Received Host Region USA East Abstract Award at ISCT 2025 for DeltEx manufacturing platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.